Cystic Fibrosis Weekly Update

Contents:

#NACFC2018 – Preclinical Study Data Demonstrate Lenabasum’s Potential to Prevent Inflammatory Signals in CF
#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators

#NACFC2018 – Preclinical Study Data Demonstrate Lenabasum’s Potential to Prevent Inflammatory Signals in CF

Oct 26, 2018 07:30 am | Alice Melão

Treatment with lenabasum can effectively prevent inflammation and induce pro-resolving signals in airway immune cells from patients with cystic fibrosis (CF), results from a preclinical study show. Lenabasum’s more recent preclinical data was discussed at the 32nd North American Cystic Fibrosis Conference, in a poster presentation titled “Lenabasum Reduces Lps-Induced Inflammation In Airway Macrophages From Human […]
The post #NACFC2018 – Preclinical Study Data Demonstrate Lenabasum’s Potential to Prevent Inflammatory Signals in CF appeared first on Cystic Fibrosis News Today.

#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators

Oct 25, 2018 07:00 am | Alice Melão

Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco (ivacaftor) and tezacaftor (VX-661) can improve the lung function of patients with cystic fibrosis (CF) with one or two copies of the CFTR F508del mutation, Phase 2 data shows. Updated results of the studies were discussed in two oral presentations at the 32nd North American Cystic Fibrosis […]
The post #NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators appeared first on Cystic Fibrosis News Today.